Agomab Therapeutics Acquires Origo Biopharma
December 15, 2021
Agomab Therapeutics NV has completed the acquisition of Spanish biotech Origo Biopharma, integrating Origo's team and facilities in Touro and Barcelona into Agomab's organization. The deal combines Origo's organ‑restricted small‑molecule platform targeting the TGF‑β pathway with Agomab's HGF‑targeting antibody programs to broaden the combined clinical‑stage pipeline for fibrosis therapeutics.
- Buyers
- Agomab Therapeutics NV
- Targets
- Origo Biopharma
- Industry
- Biotechnology
- Location
- Spain
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
AbbVie Acquires Apogee Therapeutics for $10.9 Billion
June 22, 2026
Biotechnology
AbbVie entered into a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion ($135.11 per share). The deal is intended to deepen AbbVie’s immunology portfolio and expand its clinical presence in respiratory diseases, with Apogee’s lead program zurilokibart (APG777) targeting IL-13 for atopic dermatitis and its pipeline including APG273 for asthma. Closing was expected in Q3 2026, subject to customary regulatory and shareholder approvals; AbbVie later announced completion on Sept. 3, 2026.
-
Gilead Sciences and Lakefront Biotherapeutics Acquire Ouro Medicines
March 27, 2026
Pharmaceuticals
Gilead Sciences agreed to acquire Ouro Medicines to expand its inflammation and immunology pipeline with gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases. The deal adds gamgertamig to Gilead’s portfolio and establishes Lakefront Biotherapeutics’ clinical development pipeline, with Lakefront overseeing Phase 1/2 studies and sharing upfront/milestone economics.
-
Epsilogen Acquires TigaTx to Create Pan-Isotype Cancer Antibody Company
April 7, 2025
Biotechnology
Epsilogen Ltd has completed the acquisition of Boston-based TigaTx, Inc., making TigaTx a wholly owned subsidiary. The deal combines TigaTx's engineered IgA antibody assets with Epsilogen's IgE capabilities to build a pan-isotype oncology antibody company and broaden the combined clinical-stage pipeline.
-
Valerio Therapeutics Acquires Emglev Therapeutics
September 29, 2024
Biotechnology
Valerio Therapeutics S.A. completed the acquisition of Emglev Therapeutics on September 29, 2024, transferring Emglev's proprietary synthetic single-domain antibody (sdAb) platform into a newly formed Valerio subsidiary, Valour Bio. The deal was structured as a cash sale of shares combined with a contribution-in-kind (Emglev shares exchanged for Valour Bio shares), making Emglev shareholders shareholders of Valour Bio and positioning Valour Bio to advance sdAb discovery and development across oncology and inflammatory/autoimmune indications.
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
-
Amgen Acquires Teneobio for $900M with Up to $1.6B in Milestones
July 27, 2021
Biotechnology
Amgen agreed to acquire clinical-stage biotechnology company Teneobio for $900 million in upfront cash plus potential contingent milestone payments up to $1.6 billion. The acquisition adds Teneobio's heavy-chain antibody discovery platform, bispecific/multispecific antibody technologies and a Phase 1 T-cell engager (TNB-585), strengthening Amgen's antibody research capabilities and oncology pipeline.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.